Intercept Pharmaceuticals buy Quitte
Summary
This prediction ended on 15.08.16 with a price of €144.84. The BUY prediction by Quitte for Intercept Pharmaceuticals saw massive gains of 36.86%. Quitte has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Intercept Pharmaceuticals | - | - | - | - |
| iShares Core DAX® | 1.659% | 1.586% | 18.113% | 65.562% |
| iShares Nasdaq 100 | 0.381% | 1.900% | 8.877% | 103.178% |
| iShares Nikkei 225® | 2.102% | -1.377% | 13.281% | 43.551% |
| iShares S&P 500 | 0.221% | 1.258% | 3.556% | 63.162% |
Comments by Quitte for this prediction
In the thread Intercept Pharmaceuticals diskutieren
Gerüchteküche
What: Shares ofIntercept Pharmaceuticals (NASDAQ:ICPT),a clinical stage biopharmaceutical company focused on treatingdiseases of the liver and intestines, jumped more than 27% as of 2:45p.m. EST Friday after Reuters reported that the company might belooking to sell itself.
So what: According to "sources familiarwith the matter" Intercept has been working with a group ofinvestment bankers recently to "explore the prospect of a sale."
It should be emphasized that this is still a rumor at this pointas Intercept declined to comment.
Now what: This isn't the first time that rumorshave floated around that Intercept might be a buyout target asroughly a year ago another reported surfaced saying that the companycould action itself off as it received interest from a handful oflarge pharma companies that including Gilead Sciences(NASDAQ:GILD).
If Friday's rumors do prove to be true, then Gilead Sciences mightbe an idealacquirer for Intercept as it already has a strong position theliver disease markets, so Intercept could be an interesting strategicfit. It's also worth remembering that Gilead Sciences ended 2015 with$26.2 billion in cash, so it has plenty of capital to make anacquisition if it choose to. For comparison, even with today's popIntercept's current market value is roughly $3 billion.